Benzinga | Aug 12, 2021 07:42AM EDT

VYNE Therapeutics Q2 EPS $(0.35), Inline

VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.35) per share which met the analyst consensus estimate. This is a 57.32 percent increase over losses of $(0.82) per share from the same period last year.